Lorbrena Treatment of ALK-positive Metastatic NSCLC
by Dr. C.H. Weaver M.D. updated 8/2020
The US Food and Drug Administration (FDA) granted accelerated approval to Lorbrena (lorlatinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on (Xalkori (crizotinib) and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on Alcensa (alectinib) or Zykadia (ceritinib) as the first ALK inhibitor therapy for metastatic disease in 2018.
Preliminary results of the CROWN trial were released August 8 and will be shared with the FDA and other health authorities to support full approval of Lorbrena and to seek approval for an indication that includes previously untreated ALK-positive metastatic NSCLC.
The CROWN clinical trial is a phase 3 comparative trial in which 296 people with previously untreated advanced ALK + NSCLC were treated with either Lorbrena or Xalkori and directly compared. Lorbrena was determined to be better at delaying cancer recurrence than Xalkori.
Up to 7% of NSCLC patients have an abnormal version of the ALK gene. Lung cancers with this abnormality typically occur in non-smokers. The abnormal gene contributes to the growth and development of cancer cells however several precision cancer medicines have been approved over the last few years that target ALK kinase and improve the treatment of individuals with ALK + NSCLC.
Lorbrena is a third-generation oral medication that blocks the protein produced by the abnormal ALK gene, which is determined by testing a sample of tumor tissue.
The initial approval of Lorbrena was based on a subgroup of 215 patients with ALK-positive metastatic NSCLC who were previously treated with one or more ALK kinase inhibitors. The overall response rate to Lorbrena treatment was 48%, with 4% complete and 44% partial responses. The estimated median response duration was 12.5 months.
In addition, a 60% response rate was reported among patients with measurable intracranial lesions and the median duration of response in these patients was 19.5 months.(1)
Lorbrena Shows Greater Efficacy in ALK-Positive vs ALK-Negative NSCLC
Doctors from Massachusetts General Hospital believe that ALK resistance mutations may represent a biomarker that could predict response in previously treated patients.They analyzed the baseline plasma and tumor tissue samples of 198 patients with ALK-positive NSCLC participating in a phase 2 trial of lorbrena and reported their findings in the J of Clinical Oncology.(2)
ALK mutations were detected in plasma or tissue genotyping in approximately 25% of patients. They found that among patients with resistance to crizotinib, lorbrena effectiveness was comparable between patients with and without ALK mutations. Alternatively, objective response rates were higher among patients with ALK mutations who had not responded to second-generation ALK TKI therapy versus those without ALK mutations.
Lorbrena shows greater effectiveness in patients with ALK mutations compared with patients without ALK mutations.Tumor genotyping for ALK mutations after failure of a second-generation TKI may identify patients who are more likely to derive clinical benefit.